Unnamed: 0,title,date,stock,sentiment
741248.0,"Karyopharm Therapeutics Reports Dosing Of First Patient In Phase 1/2 Study Of Selinexor In Combo With Standard Of Care Therapy For Patients With Newly Diagnosed, Recurrent Glioblastoma",2020-06-09 09:10:00-04:00,KPTI,positive
741249.0,Attention Biotech Investors: Mark Your Calendar For June PDUFA Dates,2020-06-01 16:00:00-04:00,KPTI,neutral
741250.0,20 Healthcare Stocks Moving In Friday's Pre-Market Session,2020-05-29 07:39:00-04:00,KPTI,neutral
741251.0,"The Daily Biotech Pulse: ASCO Presentations Begin, Altimmune Pops On Insider Buying, Immutep Gets R&D Grant",2020-05-29 07:22:00-04:00,KPTI,positive
741252.0,Karyopharm Reports Positive Phase 3 BOSTON Data in Oral Presentation at the American Society of Clinical Oncology 2020 Virtual Scientific Program,2020-05-28 16:12:00-04:00,KPTI,positive
741253.0,Karyopharm Therapeutics shares are trading higher after the company reported the submission of a supplemental New Drug Application to the FDA seeking approval for XPOVIO.,2020-05-20 11:05:00-04:00,KPTI,positive
741254.0,Karyopharm Therapeutics Reports Submission Of Supplemental New Drug Application For XPOVIO As Treatment For Patients With Multiple Myeloma After At Least One Prior Line Of Therapy,2020-05-20 08:18:00-04:00,KPTI,neutral
741255.0,"HC Wainwright & Co. Maintains Buy on Karyopharm Therapeutics, Lowers Price Target to $40",2020-05-06 07:06:00-04:00,KPTI,negative
741256.0,"SVB Leerink Maintains Outperform on Karyopharm Therapeutics, Lowers Price Target to $29",2020-05-05 13:14:00-04:00,KPTI,negative
741257.0,"Antengene Reports Broadened Partnership, Territory Expansion Deal With Karyopharm For Development, Commercialization Of 4 Oral Novel Drugs, Candidates",2020-05-05 08:41:00-04:00,KPTI,positive
741258.0,Recap: Karyopharm Therapeutics Q1 Earnings,2020-05-05 08:11:00-04:00,KPTI,neutral
741259.0,"The Daily Biotech Pulse: Bio-Rad's Coronavirus Test Gets EUA, Beat-And-Raise Quarter From GenMark, Adverum's Positive Gene Therapy Readout",2020-05-05 08:00:00-04:00,KPTI,positive
741260.0,"Karyopharm Therapeutics Q1 EPS $(0.780) Misses $(0.690) Estimate, Sales $18.138M Miss $21.280M Estimate",2020-05-05 07:24:00-04:00,KPTI,negative
741261.0,The Week Ahead In Biotech: Smid-Cap Earnings News Flow Picks Up Pace,2020-05-03 08:45:00-04:00,KPTI,neutral
741262.0,Karyopharm Announces Dosing Of First Patient In Randomized Study Evaluating Low Dose Selinexor In Patients With Severe Coronavirus (COVID-19),2020-04-20 07:03:00-04:00,KPTI,negative
741263.0,Komodo Health Reports Partnership With Karyopharm To Accelerate Global Clinical Trial To Treat Patients With Coronavirus,2020-04-08 10:02:00-04:00,KPTI,positive
741264.0,Karyopharm to Evaluate Low Dose Selinexor as a Potential Treatment for Hospitalized Patients with Coronavirus,2020-04-07 07:04:00-04:00,KPTI,negative
741265.0,Shares of several companies in the healthcare space are trading lower in sympathy with the overall market on continued downward momentum caused by the coronavirus. The virus has had a negative impact on the global economy.,2020-03-16 10:18:00-04:00,KPTI,negative
741266.0,Karyopharm Expands Executive Leadership Team with the Appointment of John Demaree as Chief Commercial Officer,2020-03-12 07:07:00-04:00,KPTI,positive
741267.0,Shares of several healthcare companies are trading lower. Movement appears market related amid selloff in equities. The global coronavirus outbreak has caused volatility in global markets and impacted stocks across sectors.,2020-03-11 07:15:00-04:00,KPTI,neutral
741268.0,"Benzinga's Top Upgrades, Downgrades For March 4, 2020",2020-03-04 10:08:00-05:00,KPTI,positive
741269.0,36 Healthcare Stocks Moving In Wednesday's Pre-Market Session,2020-03-04 08:00:00-05:00,KPTI,neutral
741270.0,Karyopharm Therapeutics Prices 6.25M Share Public Offering of Common Stock @$24/Share,2020-03-04 05:30:00-05:00,KPTI,positive
741271.0,"Barclays Initiates Coverage On Karyopharm Therapeutics with Overweight Rating, Announces $30 Price Target",2020-03-04 05:21:00-05:00,KPTI,negative
741272.0,85 Biggest Movers From Yesterday,2020-03-04 05:04:00-05:00,KPTI,neutral
741273.0,50 Stocks Moving In Tuesday's Mid-Day Session,2020-03-03 12:03:00-05:00,KPTI,neutral
741274.0,Karyopharm Therapeutics shares are trading lower after the company announced a proposed public offering of common stock of $150 million.,2020-03-03 08:22:00-05:00,KPTI,neutral
741275.0,"The Daily Biotech Pulse: GenMark Diagnostics Ships COVID-19 Test Kits, Karyopharm To Offer Shares, And More",2020-03-03 07:51:00-05:00,KPTI,positive
741276.0,40 Stocks Moving in Tuesday's Pre-Market Session,2020-03-03 07:31:00-05:00,KPTI,neutral
741277.0,108 Biggest Movers From Yesterday,2020-03-03 04:57:00-05:00,KPTI,neutral
741278.0,15 Stocks Moving In Monday's After-Hours Session,2020-03-02 16:50:00-05:00,KPTI,neutral
741279.0,Karyopharm Therapeutics shares are trading lower after the company announced a proposed public offering of common stock of $150 million.,2020-03-02 16:04:00-05:00,KPTI,neutral
741280.0,Karyopharm Therapeutics Announces Proposed Public Offering of Common Stock  Of $150 Million In Shares Of Common Stock,2020-03-02 16:02:00-05:00,KPTI,positive
741281.0,"HC Wainwright & Co. Maintains Buy on Karyopharm Therapeutics, Raises Price Target to $43",2020-03-02 12:11:00-05:00,KPTI,neutral
741282.0,55 Stocks Moving In Monday's Mid-Day Session,2020-03-02 11:52:00-05:00,KPTI,neutral
741283.0,30 Healthcare Stocks Moving In Monday's Pre-Market Session,2020-03-02 07:41:00-05:00,KPTI,neutral
741284.0,Karyopharm Therapeutics shares are trading higher after the company announced its Phase 3 BOSTON study met its primary endpoint with significant increase in progression-free survival in patients with multiple myeloma.,2020-03-02 07:29:00-05:00,KPTI,positive
741285.0,30 Stocks Moving in Monday's Pre-Market Session,2020-03-02 07:21:00-05:00,KPTI,neutral
741286.0,Karyopharm Announces Phase 3 BOSTON Study Meets Primary Endpoint with Significant Increase in Progression-Free Survival in Patients with Multiple Myeloma Following One to Three Prior Lines of Therapy,2020-03-02 07:05:00-05:00,KPTI,positive
741287.0,"Karyopharm Therapeutics Filing Shows Registration For Mixed Securities Offering, No Size Disclosed",2020-02-26 08:42:00-05:00,KPTI,neutral
741288.0,Shares of several healthcare and biotech companies are trading lower amid continued spread of coronavirus including notable upticks in Iran and Italy. NOTE: The virus has raised fear of a global economic slowdown.,2020-02-24 08:37:00-05:00,KPTI,negative
741289.0,25 Healthcare Stocks Moving In Wednesday's Pre-Market Session,2020-02-19 08:10:00-05:00,KPTI,neutral
741290.0,FDA Accepts Karyopharm's Supplemental New Drug Application For XPOVIO As A Treatment For Patients With Relapsed Or Refractory Diffuse Large B-Cell Lymphoma,2020-02-19 08:01:00-05:00,KPTI,positive
741291.0,"The Daily Biotech Pulse: Deciphera Cancer Drug Gets Priority Review, Fast Track Designation For Soligenix, Revolution Medicines IPO",2020-02-13 08:05:00-05:00,KPTI,negative
741292.0,"Karyopharm Therapeutics Q4 EPS $(0.76) Misses $(0.67) Estimate, Sales $17.7M Beat $16.34M Estimate",2020-02-13 07:30:00-05:00,KPTI,negative
741293.0,Karyopharm And Promedico Enter Into Exclusive Distribution Agreement To Commercialize XPOVIO In Israel,2020-02-11 07:26:00-05:00,KPTI,positive
741294.0,The Week Ahead In Biotech: SMID-Cap Earnings In The Spotlight,2020-02-09 15:22:00-05:00,KPTI,neutral
741295.0,Karyopharm Therapeutics Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4),2020-02-03 16:10:00-05:00,KPTI,positive
741296.0,"Benzinga's Top Upgrades, Downgrades For January 21, 2020",2020-01-21 09:52:00-05:00,KPTI,positive
741297.0,60 Biggest Movers From Friday,2020-01-21 04:54:00-05:00,KPTI,neutral
741298.0,"Benzinga's Top Upgrades, Downgrades For January 17, 2020",2020-01-17 13:16:00-05:00,KPTI,positive
741299.0,Wedbush Downgrades Karyopharm Therapeutics to Neutral,2020-01-17 07:34:00-05:00,KPTI,neutral
741300.0,"H.C. Wainwright Reiterates Buy on Karyopharm Therapeutics, Raises Price Target to $37",2020-01-14 07:52:00-05:00,KPTI,neutral
741301.0,"Karyopharm Sees Prelim. Q4 XPOVIO Sales $17M-$18M, Prelim. FY19 XPOVIO Sales $30M-$31M",2020-01-13 07:26:00-05:00,KPTI,neutral
741302.0,"The Daily Biotech Pulse: Positive Data Readouts To Spur Aclaris, Moderna And Ultragenyx",2020-01-10 07:13:00-05:00,KPTI,positive
741303.0,Stocks That Hit 52-Week Highs On Thursday,2020-01-09 15:15:00-05:00,KPTI,neutral
741304.0,Karyopharm Therapeutics shares are trading higher on seemingly no company-specific news to justify the price action.,2020-01-09 11:56:00-05:00,KPTI,neutral
741305.0,"Benzinga's Top Upgrades, Downgrades For January 3, 2020",2020-01-03 11:33:00-05:00,KPTI,positive
741306.0,Stocks That Hit 52-Week Highs On Friday,2019-12-27 11:27:00-05:00,KPTI,neutral
741307.0,"The Daily Biotech Pulse: Flexion Receives FDA Nod For Zilretta Label Expansion, Astellas Goes Shopping",2019-12-27 07:59:00-05:00,KPTI,neutral
741308.0,"The Daily Biotech Pulse: Qiagen Opts To Stay Solo Following Strategic Review, Spectrum Slumps On Negative Data, Microbot Medical To Offer Shares",2019-12-26 07:55:00-05:00,KPTI,negative
741309.0,"The Daily Biotech Pulse: NewLink Genetics Licenses Ovarian Cancer Dug, Correvio Awaits FDA Verdict",2019-12-24 07:24:00-05:00,KPTI,negative
741310.0,Stocks That Hit 52-Week Highs On Monday,2019-12-23 10:20:00-05:00,KPTI,neutral
741311.0,Karyopharm Submits New Drug Application to the FDA for XPOVIO as a Treatment for Patients with Relapsed or Refractory Diffuse Large B-Cell Lymphoma,2019-12-23 07:42:00-05:00,KPTI,neutral
741312.0,38 Healthcare Stocks Moving In Monday's Pre-Market Session,2019-12-09 08:26:00-05:00,KPTI,neutral
741313.0,There's A Really Good Chance You Missed One Of The Year's Best ETFs,2019-12-09 07:25:00-05:00,KPTI,positive
741314.0,Karyopharm Presents Four Posters Relating to XPOVIO at ASH 2019,2019-12-08 09:29:00-05:00,KPTI,neutral
741315.0,Karyopharm Reports New and Updated XPOVIO Data in Relapsed or Refractory Multiple Myeloma at ASH 2019,2019-12-07 14:47:00-05:00,KPTI,neutral
741316.0,Karyophram Therapeutics shares are trading lower on seemingly no company-specific news.,2019-12-06 15:37:00-05:00,KPTI,negative
741317.0,Karyopharm Therapeutics Reports Inducement Grants Under NASDAQ Listing Rule,2019-12-02 16:19:00-05:00,KPTI,positive
741318.0,Stocks That Hit 52-Week Highs On Friday,2019-11-29 10:28:00-05:00,KPTI,neutral
741319.0,Karyopharm Therapeutics shares are trading higher. Not seeing any news to justify the price action.,2019-11-29 08:55:00-05:00,KPTI,positive
741320.0,"The Daily Biotech Pulse: ChemoCentryx Triples On Data Readout, Global Blood Given FDA Nod, Positive Safety Review For Genfit's NASH Drug",2019-11-26 08:06:00-05:00,KPTI,positive
741321.0,Stocks That Hit 52-Week Highs On Monday,2019-11-25 10:19:00-05:00,KPTI,neutral
741322.0,Stocks That Hit 52-Week Highs On Friday,2019-11-22 10:17:00-05:00,KPTI,neutral
741323.0,"The Daily Biotech Pulse: Patent Win For Cellectis, Hepion Proves Efficacy In Animal Model, Job Cuts At Neon",2019-11-21 07:22:00-05:00,KPTI,positive
741324.0,Stocks That Hit 52-Week Highs On Wednesday,2019-11-20 10:12:00-05:00,KPTI,neutral
741325.0,"The Daily Biotech Pulse: Therapix To Reverse Merge With CBD Company, Crispr Gene Editing Therapy Readout",2019-11-19 07:56:00-05:00,KPTI,neutral
741326.0,Stocks That Hit 52-Week Highs On Monday,2019-11-18 11:01:00-05:00,KPTI,neutral
741327.0,Stocks That Hit 52-Week Highs On Friday,2019-11-15 10:14:00-05:00,KPTI,neutral
741328.0,"The Daily Biotech Pulse: Merck Goes Shopping, Nuvectra Files For Bankruptcy Protection, Opiant Rips Higher",2019-11-13 07:10:00-05:00,KPTI,neutral
741329.0,Stocks That Hit 52-Week Highs On Tuesday,2019-11-12 10:11:00-05:00,KPTI,neutral
741330.0,"The Daily Biotech Pulse: Reata, Kadmon Clinical Readouts, Apyx Medical's Earnings Beat",2019-11-12 07:20:00-05:00,KPTI,neutral
741331.0,Stocks That Hit 52-Week Highs On Friday,2019-11-08 10:30:00-05:00,KPTI,neutral
741332.0,Stocks That Hit 52-Week Highs On Wednesday,2019-11-06 10:10:00-05:00,KPTI,neutral
741333.0,"The Daily Biotech Pulse: Sesen Rallies On Positive FDA Meeting, Supernus Flunks Late-Stage ADHD Trial, GW Pharma Earnings",2019-11-06 08:21:00-05:00,KPTI,positive
741334.0,"UPDATE: H.C. Wainwright Maintains Buy On Karyopharm Therapeutics, Raises Target To $36 Notes 'Xpovio Launch Starts Strong'; 'Topline BOSTON data expected early 2020', 'NDA submission is expected in 2020 if the BOSTON data are positive'",2019-11-05 13:52:00-05:00,KPTI,positive
741335.0,"Karyopharm Therapeutics shares are trading higher after the company reported better-than-expected Q3 EPS and sales results. Following earnings, multiple firms maintained Buy ratings on the stock and raised the price target.",2019-11-05 13:11:00-05:00,KPTI,positive
741336.0,"Canaccord Genuity Maintains Buy on Karyopharm Therapeutics, Raises Price Target to $18",2019-11-05 11:30:00-05:00,KPTI,neutral
741337.0,"H.C. Wainwright Maintains Buy on Karyopharm Therapeutics, Raises Price Target to $36",2019-11-05 10:13:00-05:00,KPTI,neutral
741338.0,"The Daily Biotech Pulse: FDA Nod For Sanofi, BioCryst's Edema Drug In Japan, Myriad's Q1 Disappointment",2019-11-05 06:53:00-05:00,KPTI,negative
741339.0,Stocks That Hit 52-Week Highs On Monday,2019-11-04 14:43:00-05:00,KPTI,neutral
741340.0,Karyopharm Therapeutics shares are trading higher after the company reported better-than-expected Q3 EPS and sales results.,2019-11-04 09:03:00-05:00,KPTI,positive
741341.0,24 Healthcare Stocks Moving In Monday's Pre-Market Session,2019-11-04 08:13:00-05:00,KPTI,neutral
741342.0,"Karyopharm Therapeutics Q3 EPS $(0.67) Beats $(0.84) Estimate, Sales $13.149M Beat $1.8M Estimate",2019-11-04 07:35:00-05:00,KPTI,neutral
741343.0,"The Week Ahead In Biotech: Smid-Cap Earnings Deluge, SITC Conference In The Spotlight",2019-11-03 10:51:00-05:00,KPTI,neutral
741344.0,Shares of several healthcare companies are trading higher after President Trump made positive remarks on the U.S.-China trade talks as traders grew more optimistic over the possibility of a limited trade deal. Trump is scheduled to meet with Chinese Vice Premier Liu He at the White House today.,2019-10-11 11:19:00-04:00,KPTI,positive
741345.0,Shares of several healthcare companies are trading lower with the broader market after the US expanded its trade blacklist to include China's top AI firms. The US also will increase its tariffs on $250 billion worth of goods from 25% to 30% on Oct 15.,2019-10-08 10:36:00-04:00,KPTI,positive
741346.0,"Karyopharm Therapeutics shares trading lower for the third day in a row following a failed test of a resistance level at $12. After rallying for nine straight sessions, shares fell below the $11 level on Friday of last week and are below the $10 level today.",2019-09-23 14:54:00-04:00,KPTI,negative
741347.0,22 Healthcare Stocks Moving In Monday's Pre-Market Session,2019-09-16 08:29:00-04:00,KPTI,neutral
741348.0,Karyopharma Reports Royalty Deal With Healthcare Royalty Partners For Up To $150M,2019-09-16 07:11:00-04:00,KPTI,neutral
741349.0,25 Stocks Moving in Friday's Pre-Market Session,2019-09-06 08:03:00-04:00,KPTI,neutral
741350.0,86 Biggest Movers From Yesterday,2019-09-06 05:06:00-04:00,KPTI,negative
741351.0,12 Healthcare Stocks Moving In Thursday's Pre-Market Session,2019-08-22 08:47:00-04:00,KPTI,neutral
741352.0,"The Daily Biotech Pulse: ViiV's Long-Acting HIV Drug Meets Study Goal, Chinese Cheer For FibroGen, Retrophin Flunks Late-Stage Study",2019-08-22 07:18:00-04:00,KPTI,positive
741353.0,"The Daily Biotech Pulse: Sanofi's Dupixent Found Effective For Pediatric Itchy Skin, Novavax Gets Nod For Late-Stage Study, Allakos Offering",2019-08-06 07:22:00-04:00,KPTI,positive
741354.0,"Karyopharm Therapeutics Q2 EPS $(0.41) May Not Compare To $(0.98) Estimate, Sales $9.493M Beat $90K Estimate",2019-08-06 07:16:00-04:00,KPTI,neutral
741355.0,"The Week Ahead In Biotech: Focus On Earnings Deluge, Mid-Year Clinical Trial Readouts",2019-08-03 10:18:00-04:00,KPTI,neutral
741356.0,Attention Biotech Investors: Mark Your Calendar For These August PDUFA Dates,2019-07-31 17:15:00-04:00,KPTI,neutral
741357.0,45 Healthcare Stocks Moving In Monday's After-Market Session,2019-07-30 04:54:00-04:00,KPTI,neutral
741358.0,60 Biggest Movers From Yesterday,2019-07-24 04:57:00-04:00,KPTI,neutral
741359.0,45 Stocks Moving In Tuesday's Mid-Day Session,2019-07-23 13:09:00-04:00,KPTI,neutral
741360.0,"Benzinga's Top Upgrades, Downgrades For July 23, 2019",2019-07-23 11:15:00-04:00,KPTI,positive
741361.0,10 Biggest Price Target Changes For Tuesday,2019-07-23 11:03:00-04:00,KPTI,neutral
741362.0,Karyopharm Therapeutics shares are trading higher after JP Morgan upgraded the company from Neutral to Overweight and raised the price target from $8 to $16.,2019-07-23 09:31:00-04:00,KPTI,positive
741363.0,25 Stocks Moving In Tuesday's Pre-Market Session,2019-07-23 07:57:00-04:00,KPTI,neutral
741364.0,"JP Morgan Upgrades Karyopharm Therapeutics to Overweight, Raises Price Target to $16",2019-07-23 06:42:00-04:00,KPTI,neutral
741365.0,"Ivy Brain Tumor Center At Barrow Partners With Karyopharm Therapeutics To Accelerate Treatment Of Brain Cancer, No Terms Disclosed",2019-07-11 09:01:00-04:00,KPTI,negative
741366.0,30 Stocks Moving In Tuesday's Mid-Day Session,2019-07-09 12:12:00-04:00,KPTI,neutral
741367.0,Large Option Trader Dumps Karyopharm Puts Following Xpovio Approval Rally,2019-07-05 14:12:00-04:00,KPTI,positive
741368.0,HC Wainwright Hikes Karyopharm Price Target On Accelerated Drug Approval,2019-07-05 12:51:00-04:00,KPTI,positive
741369.0,24 Stocks Moving In Friday's Mid-Day Session,2019-07-05 12:41:00-04:00,KPTI,neutral
741370.0,"Benzinga Pro's Top 7 Most-Searched Tickers For Morning of Friday., July 05, 2019",2019-07-05 10:21:00-04:00,KPTI,positive
741371.0,5 Biggest Price Target Changes For Friday,2019-07-05 09:44:00-04:00,KPTI,neutral
741372.0,"The Daily Biotech Pulse: FDA Approves Karyopharm's Blood Cancer Treatment, Grifols' Immunodeficiency Drug; ESMO, ISTH Conferences In The Spotlight",2019-07-05 08:55:00-04:00,KPTI,negative
741373.0,21 Stocks Moving In Friday's Pre-Market Session,2019-07-05 08:45:00-04:00,KPTI,neutral
741374.0,A Peek Into The Markets: US Stock Futures Down; All Eyes On Jobs Report,2019-07-05 08:15:00-04:00,KPTI,neutral
741375.0,"Karyopharm Therapeutics shares are trading higher on continued strength after the company on Wednesday announced FDA approval of XPOVIO for treatment of patients with relapsed, refractory multiple myeloma.",2019-07-05 07:44:00-04:00,KPTI,positive
741376.0,Karyopharm Therapeutics Shares Rise 21% Premarket; Baird Raises Price Target to $25 from $15,2019-07-05 06:04:00-04:00,KPTI,positive
741377.0,48 Biggest Movers From Wednesday,2019-07-05 05:08:00-04:00,KPTI,neutral
741378.0,UPDATE: Karyopharm Shares Pullback From High But Still Up 31% For Session,2019-07-03 13:36:00-04:00,KPTI,positive
741379.0,"Karyopharm Therapeutics Shares Resume Trade, Move Lower",2019-07-03 13:35:00-04:00,KPTI,neutral
741380.0,Karyopharm Therapeutics Shares To Resume Trade At 1:35 p.m. EDT,2019-07-03 13:20:00-04:00,KPTI,positive
741381.0,Karyopharma 8-K Shows Chief Commercial Officer Anand Varadan Resigned,2019-07-03 13:19:00-04:00,KPTI,negative
741382.0,"Karyopharm Reports FDA Approval Of XPOVIO (selinexor) For Treatment Of Patients With Relapsed, Refractory Multiple Myeloma",2019-07-03 13:10:00-04:00,KPTI,positive
741383.0,33 Stocks Moving In Wednesday's Mid-Day Session,2019-07-03 12:47:00-04:00,KPTI,neutral
741384.0,'FDA approves new treatment for refractory multiple myeloma' -FDA Release On Karyopharm's Selinexor,2019-07-03 12:46:00-04:00,KPTI,positive
741385.0,Mid-Day Market Update: Dow Rises Over 150 Points; OMNOVA Solutions Shares Spike Higher,2019-07-03 12:29:00-04:00,KPTI,positive
741386.0,Karyopharm Spikes Higher After Selinexor Leak,2019-07-03 12:04:00-04:00,KPTI,negative
741387.0,Karyopharm Therapeutics shares trading higher following chatter the company's website for Selinexor went live.,2019-07-03 11:20:00-04:00,KPTI,positive
741388.0,Karyopharma Shares Halted News Pending,2019-07-03 11:06:00-04:00,KPTI,positive
741389.0,"UPDATE On Karyopharm Upside: STAT News' Adam Feuerstein Recently Replied To Tweet, Saying '...I'm still seeing the website behind a firewall. Did someone ""oops""?'",2019-07-03 10:49:00-04:00,KPTI,neutral
741390.0,"Upside In Karyopharm Shares Being Attributed To Unconfirmed Chatter Co.'s Selinexor Website Is Live, Word Of 'Apparent Accelerated Approval'",2019-07-03 10:43:00-04:00,KPTI,positive
741391.0,"Karyopharm Therapeutics Shares Resume Trade, Up 14.5%",2019-07-03 10:40:00-04:00,KPTI,positive
741392.0,"Karyopharm Therapeutics Shares Halted On Circuit Breaker, Up 8.4%",2019-07-03 10:35:00-04:00,KPTI,positive
741393.0,44 Biggest Movers From Yesterday,2019-07-03 05:24:00-04:00,KPTI,neutral
741394.0,Attention Biotech Investors: Mark Your Calendar For These July PDUFA Dates,2019-07-01 07:14:00-04:00,KPTI,neutral
741395.0,The Week Ahead In Biotech: Pending Clinical Readouts In Focus,2019-06-29 08:25:00-04:00,KPTI,neutral
741396.0,Karyopharm Therapeutics Offers Updated Data From Phase 2b SADAL Study At International Conference on Malignant Lymphoma,2019-06-19 11:07:00-04:00,KPTI,neutral
741397.0,Shares of several companies in the biotech space are trading higher after Pfizer announced it will acquire Array BioPharma.,2019-06-17 10:10:00-04:00,KPTI,positive
741398.0,Karyopharm Reports New and Updated Selinexor Combination Data from the Phase 1b/2 STOMP Study at the European Hematology Association 2019 Annual Meeting,2019-06-14 07:03:00-04:00,KPTI,neutral
741399.0,55 Biggest Movers From Yesterday,2019-05-23 04:56:00-04:00,KPTI,neutral
741400.0,36 Stocks Moving In Tuesday's Mid-Day Session,2019-05-21 12:31:00-04:00,KPTI,neutral
741401.0,"Karyopharm Therapeutics Announces That Five Abstracts Relating To Selinexor Will Be Presented At The Upcoming European Hematology Association 2019 Annual Meeting Taking Place June 13-16, 2019 In Amsterdam",2019-05-16 11:09:00-04:00,KPTI,neutral
741402.0,"The Daily Biotech Pulse: Novartis Goes Shopping, Mixed Trial Results For Provention Bio, 4 Stocks To Debut",2019-05-09 07:56:00-04:00,KPTI,neutral
741403.0,Karyopharm Therapeutics Q1 EPS $(1.09) Misses $(0.87) Estimate,2019-05-09 07:18:00-04:00,KPTI,negative
741404.0,31 Stocks Moving In Thursday's Pre-Market Session,2019-03-21 07:50:00-04:00,KPTI,neutral
741405.0,60 Biggest Movers From Yesterday,2019-03-19 05:24:00-04:00,KPTI,neutral
741406.0,75 Biggest Movers From Friday,2019-03-18 05:22:00-04:00,KPTI,neutral
741407.0,51 Stocks Moving In Friday's Mid-Day Session,2019-03-15 12:45:00-04:00,KPTI,neutral
741408.0,FDA Delays Selinexor Approval By 3 Months — So Why Is Karyopharm Ripping Higher?,2019-03-15 12:34:00-04:00,KPTI,positive
741409.0,Karyopharm shares are trading higher after the company announced FDA extension on the review period for its Selinexor New Drug Application.,2019-03-15 08:50:00-04:00,KPTI,positive
741410.0,32 Stocks Moving In Friday's Pre-Market Session,2019-03-15 08:25:00-04:00,KPTI,neutral
741411.0,"The Daily Biotech Pulse: KaryoPharm's Selinexor Review Delayed, FDA Accepts Adamis Opioid Overdose Drug NDA",2019-03-15 07:39:00-04:00,KPTI,positive
741412.0,Karyopharm shares are trading higher after the company announced FDA extension of the review period for its Selinexor New Drug Application.,2019-03-14 17:52:00-04:00,KPTI,positive
741413.0,Karyopharm Announces FDA Extension Of Review Period For Selinexor New Drug Application,2019-03-14 16:59:00-04:00,KPTI,neutral
741414.0,"The Daily Biotech Pulse: Puma Biotech Earnings, Mersana Offering, Orphan Drug Designation For Ascendis",2019-03-01 08:50:00-05:00,KPTI,neutral
741415.0,"JP Morgan Downgrades Karyopharm Therapeutics to Neutral, Lowers Price Target to $7",2019-03-01 06:48:00-05:00,KPTI,positive
741416.0,"The Daily Biotech Pulse: Bristol-Myers Squibb-Celgene Deal Faces Setback, Syneos Hit By SEC Probe, FDA Cheer For T2 Biosystems",2019-02-28 08:24:00-05:00,KPTI,positive
741417.0,"Karyopharm Therapeutics Q4 EPS $(0.96) Down From $(0.80) YoY, Sales $206K Down From $1.534M YoY",2019-02-28 07:18:00-05:00,KPTI,neutral
741418.0,84 Biggest Movers From Yesterday,2019-02-28 05:10:00-05:00,KPTI,neutral
741419.0,72 Stocks Moving In Wednesday's Mid-Day Session,2019-02-27 12:20:00-05:00,KPTI,neutral
741420.0,Analysts Slash KaryoPharm Price Targets By Over 50% After Adcom Setback,2019-02-27 11:31:00-05:00,KPTI,negative
741421.0,10 Biggest Price Target Changes For Wednesday,2019-02-27 10:22:00-05:00,KPTI,neutral
741422.0,"Wedbush Maintains Outperform on Karyopharm Therapeutics, Lowers Price Target to $6",2019-02-27 08:47:00-05:00,KPTI,negative
741423.0,35 Stocks Moving In Wednesday's Pre-Market Session,2019-02-27 08:25:00-05:00,KPTI,neutral
741424.0,"The Daily Biotech Pulse: FDA Panel Vote Sinks KaryoPharm, Refuse-To-file Letter For Adamis, Tandem Diabetes Earnings",2019-02-27 08:13:00-05:00,KPTI,neutral
741425.0,Bank of America Downgrades Karyopharm Therapeutics to Underperform,2019-02-27 06:38:00-05:00,KPTI,neutral
741426.0,UPDATE: Karyopharma Says 'we plan to work with the FDA to evaluate the best path forward as they continue to review our NDA',2019-02-26 17:52:00-05:00,KPTI,positive
741427.0,Karyopharma Reports FDA AdCom Panel Reviewing Selinexor For Treatment Of Patients With Triple Class Refractory Multiple Myeloma Voted 8-5 Recommending FDA Wait For Results From Phase 3 BOSTON Study Before Making Final Decision Related To Approval,2019-02-26 17:52:00-05:00,KPTI,positive
741428.0,"FDA Oncologic Drugs Advisory Committee Is Holding A Meeting Today From 12:30-5:00PM ET To Discuss Karyopharm's New Drug Application Requesting Accelerated Approval For Selinexor, A First-In-Class, Oral Selective Inhibitor Of Nuclear Export Comp",2019-02-26 12:35:00-05:00,KPTI,positive
741429.0,Karyopharm Shares Halted News Pending,2019-02-26 12:25:00-05:00,KPTI,positive
741430.0,"The Daily Biotech Pulse: Immunomedics CEO Departs, Ultragenyx Offering, Karyopharm Awaits FDA Panel Vote",2019-02-26 07:56:00-05:00,KPTI,positive
741431.0,"'Karyopharm hides higher death rate tied to blood cancer drug, dimming approval hopes' -STAT News",2019-02-25 10:10:00-05:00,KPTI,negative
741432.0,28 Stocks Moving In Monday's Pre-Market Session,2019-02-25 08:00:00-05:00,KPTI,neutral
741433.0,Karyopharm Announces Michael Mason CFO,2019-02-25 07:05:00-05:00,KPTI,neutral
741434.0,71 Biggest Movers From Friday,2019-02-25 05:04:00-05:00,KPTI,neutral
741435.0,Karyopharm Therapeutics Option Alert: Mar 15 $10 Calls Sweep (38) near the Bid: 1018 @ $0.253 vs 3696 OI; Earnings 3/14 Before Open [est] Ref=$5.285,2019-02-22 15:19:00-05:00,KPTI,positive
741436.0,Karyopharm Shares Nosedive On Tough FDA Briefing For Multiple Myeloma Drug,2019-02-22 15:15:00-05:00,KPTI,positive
741437.0,"The Week Ahead In Biotech: Conferences, PDUFA Dates, Clinical Trials, Earnings, IPOs",2019-02-22 13:55:00-05:00,KPTI,neutral
741438.0,Karyopharm Therapeutics shares are trading lower after the FDA AdCom panel for Elinexor showed the FDA staff is unclear whether the treatment provides a clinically meaningful benefit which outweighs risks.,2019-02-22 13:27:00-05:00,KPTI,positive
741439.0,"Karyopharm Shares Resume Trade, Rebound From Lows, Down 37% For Session",2019-02-22 12:57:00-05:00,KPTI,positive
741440.0,UPDATE: FDA Briefing Doc For Karyopharm AdCom Panel On Selinexor Shows FDA Staff Is Unclear Whether Treatment Provides Clinically Meaningful Benefit Which Outweighs Risks,2019-02-22 12:47:00-05:00,KPTI,positive
741441.0,"Karyopharm Shares Halted On Circuit Breaker, Down 16.5%",2019-02-22 12:33:00-05:00,KPTI,positive
741442.0,"Karyopharm Shares Dip To Session Low, Now Down 12.5% As Traders Circulate FDA Briefing Doc For Co.'s Feb. 26, 2019 AdCom Panel Meeting On Selinexor",2019-02-22 12:31:00-05:00,KPTI,neutral
741443.0,"Karyopharm Reports FDA Panel To Review Selinexor For Treatment of Patients with Triple Class Refractory Multiple Myeloma Who Have Received At Least Three Prior Therapies On Feb. 26, 2019 At 12:30 p.m. EST",2019-02-07 08:44:00-05:00,KPTI,neutral
741444.0,Karyopharm Therapeutics Option Alert: Mar 15 $7.5 Puts Sweep (18) near the Bid: 675 @ $0.401 vs 5 OI; Earnings 3/14 Before Open [est] Ref=$9.0,2019-02-06 12:53:00-05:00,KPTI,positive
741445.0,Karyopharma Reports Submission Of Marketing Authorization Application To EMA For Selinexor As Treatment For Patients With Pentra-Refractory Multiple Myeloma,2019-01-08 12:20:00-05:00,KPTI,neutral
741446.0,Bank of America Upgrades Karyopharm Therapeutics to Neutral,2019-01-03 07:48:00-05:00,KPTI,neutral
741447.0,"The Daily Biotech Pulse: Tilray Inks Cannabis Drink Pact, Double Delight For Merck, FDA Snub For Spectrum",2018-12-20 07:53:00-05:00,KPTI,positive
741448.0,46 Stocks Moving In Monday's Mid-Day Session,2018-12-03 12:37:00-05:00,KPTI,neutral
741449.0,Karyopharm Reports Updated Selinexor Data from the Phase 2b STORM and Phase 1b/2 STOMP Studies in Relapsed/Refractory Multiple Myeloma at ASH 2018,2018-12-03 11:01:00-05:00,KPTI,neutral
741450.0,28 Stocks Moving In Monday's Pre-Market Session,2018-12-03 08:13:00-05:00,KPTI,neutral
741451.0,"The Week Ahead In Biotech: ASH 2018, PDUFA Dates, Clinical Trials And Earnings",2018-11-25 09:41:00-05:00,KPTI,neutral
741452.0,Wedbush Upgrades Karyopharm Therapeutics to Outperform,2018-11-09 07:27:00-05:00,KPTI,neutral
741453.0,"The Daily Biotech Pulse: Nantkwest Reports Positive Cancer Vaccine Trial Results, Sarepta Offering",2018-11-08 08:10:00-05:00,KPTI,negative
741454.0,"Karyopharm Therapeutics Q3 EPS $(0.79) Beats $(0.89) Estimate, Sales $239K Miss $460K Estimate",2018-11-08 07:14:00-05:00,KPTI,negative
741455.0,Karyopharma Reports FDA Issued Fast Track Designation For Selinexor For Treatment Of Patients With Relapsed Or Refractory Diffuse Large B-Cell Lymphoma,2018-11-07 08:08:00-05:00,KPTI,neutral
741456.0,"The Week Ahead In Biotech: Earnings, Conferences, PDUFA Dates, Clinical Trial Results And IPOs",2018-11-04 13:35:00-05:00,KPTI,neutral
741457.0,"Karyopharm Therapeutics Reports CFO, Treasurer, Mike Falvey, To Leave; Exec. Search Will Commence Immediately",2018-10-26 07:02:00-04:00,KPTI,positive
741458.0,41 Biggest Movers From Yesterday,2018-10-11 05:22:00-04:00,KPTI,neutral
741459.0,41 Stocks Moving In Wednesday's Mid-Day Session,2018-10-10 12:54:00-04:00,KPTI,neutral
741460.0,FDA On Friday Accepted Karyopharm's New Drug Application For Selinexor And Granted Priority Review,2018-10-08 07:37:00-04:00,KPTI,positive
741461.0,"The Daily Biotech Pulse: FDA Nod For STAAR, Supernus Opens Wallet, Principia Biopharma To Debut",2018-09-14 08:38:00-04:00,KPTI,neutral
741462.0,"Stocks Which Set New 52-Week High Yesterday, August 30th",2018-08-31 10:11:00-04:00,KPTI,neutral
741463.0,"The Daily Biotech Pulse: FDA Blessings for Merck's HIV Drug Combo, Veracyte's Test Gets Medicare Coverage",2018-08-31 08:29:00-04:00,KPTI,positive
741464.0,"The Daily Biotech Pulse: Assertio Settles With Purdue, Emergent Biosolutions In M&A Mix, Novartis Eye Care Unit Recalls Stent",2018-08-29 07:54:00-04:00,KPTI,positive
741465.0,Form 4 Filing Late Thursday Showed Karyopharm Therapeutics 10% Owner Chione Ltd Sold a Total of 80.876K Shares at Avg. Prices Ranging From $18.50-$18.71,2018-08-10 09:53:00-04:00,KPTI,positive
741466.0,"The Daily Biotech Pulse: FDA Snub For Gemphire, Ligand Earnings, Insmed's Antibiotic Faces FDA Panel",2018-08-07 08:23:00-04:00,KPTI,negative
741467.0,"Karyopharm Therapeutics Q2 EPS $(0.60) Beats $(0.81) Estimate, Sales $19.891M Beat $3.09M Estimate",2018-08-07 07:08:00-04:00,KPTI,neutral
741468.0,Karyopharm Therapeutics Reports Completed Rolling Submission Of New Drug Application For Selinexor As Treatment For Patients With Penta-Refractory Multiple Myeloma,2018-08-06 16:23:00-04:00,KPTI,neutral
741469.0,"Karyopharm Initiates Rolling Submission of New Drug Application To FDA For Selinexor, Company Plans to Complete Submission During the Second Half of 2018",2018-07-18 07:02:00-04:00,KPTI,neutral
741470.0,"Karyopharm Therapeutics Filing Shows Registration For Mixed Securities Shelf Offering, Includes Maximum Offer Value ~$151.5M For Secondary Offering",2018-07-02 16:18:00-04:00,KPTI,positive
741471.0,"Benzinga's Daily Biotech Pulse: Hematology Conference In The Spotlight, Dr. Reddy To Launch Generic Opioid Addiction Drug",2018-06-15 09:13:00-04:00,KPTI,neutral
741472.0,UPDATE: Karyopharm On Updated Selinexor Phase 1b/2 STOMP Data: SPd All Oral Regimen Shows Strong Response Rates: 55% ORR in Pomalyst-Naïve and Revlimid-Relapsed or -Refractory MM with PFS of 11.6 months; 50% ORR in the Overall Study Population,2018-06-15 07:10:00-04:00,KPTI,positive
741473.0,UPDATE: Karyopharm On Updated Selinexor Phase 1b/2 STOMP Data: 82% ORR in Patients with Heavily Pretreated Darzalex-Naïve MM; 68% ORR in the Overall Study Population,2018-06-15 07:10:00-04:00,KPTI,neutral
741474.0,Karyopharm Offers Updated Selinexor Phase 1b/@ STOMP Myeloma Data Showed 17.8-month PFS and 83% ORR in the BOSTON Multiple Myeloma (MM) Population; 63% ORR in the Overall Study Population,2018-06-15 07:10:00-04:00,KPTI,neutral
741475.0,"Karyopharma Therapeutics Earlier Issued 8-K Which Shows Slideshow For Corporate Presentation, Includes Expectation For FY18 Operating Cash Burn $175M-$185M",2018-06-07 07:24:00-04:00,KPTI,neutral
741476.0,The Week Ahead In Biotech: ASCO Presentations In The Spotlight,2018-05-26 11:07:00-04:00,KPTI,neutral
741477.0,45 Biggest Movers From Yesterday,2018-05-25 04:37:00-04:00,KPTI,neutral
741478.0,42 Stocks Moving In Thursday's Mid-Day Session,2018-05-24 13:31:00-04:00,KPTI,neutral
741479.0,"Benzinga's Top Upgrades, Downgrades For May 24, 2018",2018-05-24 09:40:00-04:00,KPTI,positive
741480.0,"The Market In 5 Minutes: GE, Tariffs, Summit, Jobless Claims And More",2018-05-24 09:05:00-04:00,KPTI,neutral
741481.0,"UPDATE: Karyopharm Will Receive $12M Upfront, Eligible To Receive Up To $150M In Future Milestones Plus Royalties",2018-05-24 07:07:00-04:00,KPTI,neutral
741482.0,"Karyopharm, Antengene Report Signing Of Exclusive License Deal To Develop, Commercialize Selinexor, Eltanexor, Verdinextor, KPT-9274 In China, Other Regions In Asia",2018-05-24 07:06:00-04:00,KPTI,positive
741483.0,Wedbush Downgrades Karyopharm Therapeutics to Neutral,2018-05-24 06:26:00-04:00,KPTI,neutral
741484.0,"Benzinga's Daily Biotech Pulse: AstraZeneca's Q1, Novartis-Amgen Migraine Drug Approved",2018-05-18 08:00:00-04:00,KPTI,positive
741485.0,"Benzinga's Daily Biotech Pulse: ARMO Skyrockets On Eli Lilly Deal, Akcea Meets FDA Panel, vTv Alzheimer's Trial Results",2018-05-10 09:44:00-04:00,KPTI,neutral
741486.0,"Karyopharm Therapeutics Q1 EPS $(0.78) Misses $(0.62) Estimate, Sales $10M Beat $5.84M Estimate",2018-05-10 07:12:00-04:00,KPTI,negative
741487.0,"The Week Ahead In Biotech: PDUFA Dates, Earnings, IPOs And More",2018-05-06 18:19:00-04:00,KPTI,neutral
741488.0,"12 Biggest Movers Of The Week: Snap, Tenet, Wayfair And More",2018-05-04 16:48:00-04:00,KPTI,neutral
741489.0,Karyopharm Therapeutics Prices ~9.15M Share Offering of Common Stock @$14.75/Share,2018-05-03 03:57:00-04:00,KPTI,positive
741490.0,42 Biggest Movers From Yesterday,2018-05-02 05:31:00-04:00,KPTI,neutral
741491.0,Karyopharm Therapeutics Announces $125M Common Stock Offering,2018-05-01 16:33:00-04:00,KPTI,neutral
741492.0,"Benzinga Pro's Most-Searched Tickers For Afternoon Of May 1, 2018",2018-05-01 14:01:00-04:00,KPTI,neutral
741493.0,32 Stocks Moving In Tuesday's Mid-Day Session,2018-05-01 13:04:00-04:00,KPTI,neutral
741494.0,21 Stocks Moving In Tuesday's Pre-Market Session,2018-05-01 08:32:00-04:00,KPTI,neutral
741495.0,Benzinga Pro's 5 Stocks To Watch Today,2018-05-01 08:24:00-04:00,KPTI,neutral
741496.0,"Benzinga's Daily Biotech Pulse: Karyopharm's STORM Study, Inogen Rallies On Earnings",2018-05-01 07:51:00-04:00,KPTI,neutral
741497.0,36 Biggest Movers From Yesterday,2018-05-01 05:02:00-04:00,KPTI,neutral
741498.0,Karyopharm Therapeutics Inc Shares Up 20.8% After Hours Following Positive Trial Data From STORM Study For Selinexor; Co. To Submit NDA For Selinexor For Penta-Refractory Multiple Myeloma During 2H'18,2018-04-30 17:19:00-04:00,KPTI,positive
741499.0,"Karyopharm Shares Resume Trade, Now Up 26.2%",2018-04-30 16:37:00-04:00,KPTI,positive
741500.0,Karyopharm Shares To Resume Trade At 4:35 p.m. EDT,2018-04-30 16:20:00-04:00,KPTI,positive
741501.0,Karyopharm Says Plans To Submit NDA For Selinexor For Penta-Refractory Multiple Myeloma During 2H'18,2018-04-30 16:10:00-04:00,KPTI,neutral
741502.0,"UPDATE: Karyopharm Says, Related To Primary Objective Of STORM Study For Selinexor, Results Included 2 Complete Responses, 29 Partial Or Very Good Partial Responses",2018-04-30 16:10:00-04:00,KPTI,positive
741503.0,"Karyopharm Reports Top-Line Data From Phase 2b STORM Study Evaluating Selinexor In Patients With Penta-Refractory Multiple Myeloma: Achieved 25.4% Overall Response Rate, Median Duration Response Of 4.4 Mos.",2018-04-30 16:08:00-04:00,KPTI,neutral
741504.0,Karyopharma Shares Halted News Pending,2018-04-30 16:02:00-04:00,KPTI,positive
741505.0,36 Stocks Moving In Monday's Mid-Day Session,2018-04-30 13:16:00-04:00,KPTI,neutral
741506.0,"The Week Ahead In Biotech: PDUFA Dates, Clinical Trials, Merck And Pfizer Earnings On Tap",2018-04-29 08:11:00-04:00,KPTI,neutral
741507.0,36 Biggest Movers From Yesterday,2018-04-11 05:17:00-04:00,KPTI,neutral
741508.0,25 Stocks Moving In Tuesday's Mid-Day Session,2018-04-10 12:40:00-04:00,KPTI,neutral
741509.0,Benzinga Pro's 5 Stocks To Watch Today,2018-04-10 08:42:00-04:00,KPTI,neutral
741510.0,25 Stocks Moving In Tuesday's Pre-Market Session,2018-04-10 07:53:00-04:00,KPTI,neutral
741511.0,Karyopharm's Selinexor Receives Fast Track Designation from FDA for the Treatment of Patients with Penta-Refractory Multiple Myeloma,2018-04-10 07:12:00-04:00,KPTI,neutral
741512.0,"Karyopharm Says Cash, Cash Equivalents, Investments Will Be Sufficient To Fund Operations Through At Least Q1'19",2018-03-15 07:07:00-04:00,KPTI,neutral
741513.0,Karyopharm Therapeutics Reports Q4 EPS $(0.80) vs $(0.65) Est.,2018-03-15 07:07:00-04:00,KPTI,neutral
741514.0,"The Week Ahead In Biotech: Earnings, PDUFA Dates And More",2018-03-11 16:58:00-04:00,KPTI,neutral
741515.0,RBC Raises Karyopharm Therapeutics Price Target From $15 To $22 As Firm Believes Co.'s Valuation Relative To Other Small-Cap Oncology Co.'s Doesn't Reflect selinexor's Market Opportunity,2018-03-02 12:33:00-05:00,KPTI,positive
741516.0,Karyopharm Therapeutics S-3 Shows Registration For $250M Mixed Securities Shelf Offering,2018-01-26 16:30:00-05:00,KPTI,positive
741517.0,44 Biggest Movers From Yesterday,2018-01-26 04:43:00-05:00,KPTI,neutral
741518.0,Benzinga Pro's 4 Stocks To Watch Today,2018-01-25 09:11:00-05:00,KPTI,neutral
741519.0,Biogen to Acquire Karyopharm's KPT-350 for $10M Upfront an Up to An Additional $207M in Milestones and Royalties,2018-01-25 06:43:00-05:00,KPTI,neutral
741520.0,"Karyopharm Earlier Reported Phase 1/2 Eltanexor Data At ASH: Showed Candidate Is Well Tolerated, Demonstrated Promising Activity",2017-12-11 09:14:00-05:00,KPTI,positive
741521.0,Karyopharm Presents Positive Selinexor Data from the Phase 1b/2 STOMP Study at #ASH2017,2017-12-11 04:01:00-05:00,KPTI,positive
741522.0,"Benzinga's Top Upgrades, Downgrades For November 15, 2017",2017-11-15 09:13:00-05:00,KPTI,positive
741523.0,"H.C. Wainwright Assumes Karyopharm Therapeutics at Buy, Announces price target $23.00",2017-11-15 07:08:00-05:00,KPTI,neutral
741524.0,13G Filing From Point72 Asset Mgmt Reporting 7.3% Stake In Karyopharm Therapeutics,2017-11-06 17:33:00-05:00,KPTI,positive
741525.0,"Seeing Notable Block Trade In Karyopharm, 2M Shares At $10.80/Share",2017-11-03 13:50:00-04:00,KPTI,negative
741526.0,"Karyopharm Reports Q3 EPS $(0.65) vs. $(0.65) Est., Sales $0 vs. $30K Est.",2017-11-02 09:58:00-04:00,KPTI,neutral
741527.0,Benzinga's Option Alert Recap From October 16,2017-10-16 16:34:00-04:00,KPTI,positive
741528.0,Karyopharm Option Alert: May 18 $12.5 Calls at the Bid: 500 @ $2.15 vs 51 OI; Ref=$11.3325,2017-10-16 15:00:00-04:00,KPTI,positive
741529.0,30 Stocks Moving In Thursday's Pre-Market Session,2017-10-12 08:03:00-04:00,KPTI,neutral
741530.0,"Karyopharm, Ono Pharmaceutical Sign Exclusive License Agreement to Develop and Commercialize Selinexor and KPT-8602 in Japan; Other Countries in Asia; Karyopharm to Receive $22.5M Upfront Payment",2017-10-12 04:00:00-04:00,KPTI,positive
741531.0,15 Biggest Mid-Day Gainers For Wednesday,2017-09-20 12:26:00-04:00,KPTI,neutral
741532.0,28 Stocks Moving In Wednesday's Pre-Market Session,2017-09-20 08:08:00-04:00,KPTI,neutral
741533.0,"Karyopharm Reports SEAL Study's Primary Endpoint Of Progression-Free Survival Showed Superiority Over Placebo, Demonstrating Hazard Ratio Of 0.60, Representing 40% Reduction In Risk Of Progression Or Death",2017-09-20 07:05:00-04:00,KPTI,negative
741534.0,RBC Initiated Coverage On 33 Pharma/Biotech Cos.,2017-09-15 07:38:00-04:00,KPTI,neutral
741535.0,Karyopharm Names Michael Falvey CFO,2017-09-12 16:06:00-04:00,KPTI,neutral
741536.0,UPDATE: Karyopharm Says 'Top-line Phase 1 KPT-9274 Data Show a Manageable Safety Profile and Early Signals of Anti-Tumor Activity',2017-09-08 07:04:00-04:00,KPTI,positive
741537.0,"Karyopharm Reports Presentation Of Selinexor, KPT-9274 Data: Showed 'Encouraging Early Efficacy in Patients with Ovarian and Endometrial Cancers'",2017-09-08 07:04:00-04:00,KPTI,positive
741538.0,"Karyopharm Q2 EPS $(0.64) vs $(0.65) Est., Sales $3K vs $120K Est.",2017-08-08 07:29:00-04:00,KPTI,neutral
741539.0,22 Stocks Moving In Monday's Pre-Market Session,2017-07-10 08:24:00-04:00,KPTI,neutral
741540.0,"UPDATE: Karyopharm Reports Objective Response Rate To 33.3% Overall, 35% In Patients With Double Or Triple Hit DLBCL",2017-06-23 06:32:00-04:00,KPTI,neutral
741541.0,Karyopharm Therapeutics Reports Updated Phase 2b SADAL Data For Selinexor In Diffuse Large B-Cell Lymphoma,2017-06-23 06:30:00-04:00,KPTI,neutral
741542.0,Karyopharma Reports Dosing Of First Patient In Pivotal Phase 3 BOSTON Study Evaluating Selinexor In Patients With Relapsed/Refractory Multiple Myeloma,2017-06-07 16:05:00-04:00,KPTI,neutral
741543.0,"Karyopharm Therapeutics Q1 EPS $(0.71) vs $(0.67) Est, No Sales",2017-05-04 09:24:00-04:00,KPTI,negative
741544.0,"Karyopharm and Anivive Lifesciences Sign Exclusive License Agreement For Verdinexor, Karyopharm To Receive $1M Upfront Payment, Eligible to Receive Up To $43.5M In Future Payments",2017-05-03 16:09:00-04:00,KPTI,positive
741545.0,Karyopharm Therapeutics Prices Offering of ~3.9M Shares at $10.25/Share,2017-04-25 09:22:00-04:00,KPTI,positive
741546.0,Karyopharm Announces $40M Offering Common Stock,2017-04-24 16:04:00-04:00,KPTI,neutral
741547.0,"Karyopharm Offers Interim Phase 2b SADAL Data (Selinexor): Achieved Robust and Prolonged Response Rates in Patients with Relapsed or Refractory DLBCL, 28.6% Overall Response Rate",2017-04-04 13:02:00-04:00,KPTI,positive
741548.0,"Medidata, Karyopharm Report Expansion of Clinical Trial Partnership",2017-04-04 08:31:00-04:00,KPTI,neutral
741549.0,"Karyopharm Therapeutics Reports Stepping Down of CFO, Treasruer Justin Renz; Michael Todisco Named Interim Replacement",2017-04-03 16:06:00-04:00,KPTI,neutral
741550.0,Karyopharm Therapeutics Reports FDA Division of Hematology Products Lifts Partial Clinical Hold on Selinexor Trials,2017-03-30 07:01:00-04:00,KPTI,neutral
741551.0,Karyopharm Reports Q4 EPS $(0.65) vs $(0.66) Est.,2017-03-16 07:34:00-04:00,KPTI,neutral
741552.0,20 Stocks Moving In Monday's Pre-Market Session,2017-03-13 08:24:00-04:00,KPTI,neutral
741553.0,15 Biggest Mid-Day Losers For Friday,2017-03-03 13:20:00-05:00,KPTI,negative
741554.0,22 Stocks Moving In Friday's Pre-Market Session,2017-03-03 08:28:00-05:00,KPTI,neutral
741555.0,An Expected Failure From Karyopharm's Selinexor Doesn't Change The Bull Thesis,2017-03-03 08:27:00-05:00,KPTI,negative
741556.0,Karyopharm Shares to Resume Trade at 4:35 p.m. EST,2017-03-02 16:22:00-05:00,KPTI,positive
741557.0,"Karyopharm Announces Phase 2 SOPRA Study Results, Selinexor Did Not Meet Primary Endpoint",2017-03-02 16:19:00-05:00,KPTI,neutral
741558.0,Karyopharm Therapeutics Shares Halted News Pending,2017-03-02 16:03:00-05:00,KPTI,positive
741559.0,25 Biggest Mid-Day Gainers For Thursday,2017-03-02 12:39:00-05:00,KPTI,neutral
741560.0,"Leerink Partners Global Healthcare Conference Concludes Today; Presenters Include Aurinia Pharmaceuticals, Karyopharm Therapeutics, Selecta Biosciences, TESARO, EXACT Sciences, Axovant Sciences, Achaogen",2017-02-16 08:20:00-05:00,KPTI,neutral
741561.0,Key Presenters At Leerink's Healthcare Conference,2017-02-13 15:52:00-05:00,KPTI,neutral
741562.0,"Canaccord Genuity Rare Disease Biopharma One-On-One Day Takes Place Today; Presenters Include Aurinia Pharmaceuticals, Akari Therapeutics, Karyopharm, Selecta Biosciences, Aptose Biosciences, And Gemphire Therapeutics",2017-02-07 08:40:00-05:00,KPTI,neutral
741563.0,Here's Your Sell-Side Conference Preview,2017-02-06 15:42:00-05:00,KPTI,neutral
741564.0,Novan CEO Talks About The Company's Future: 'Our Focus Is Put On SB204',2016-12-09 18:39:00-05:00,KPTI,neutral
741565.0,"Karyopharm Therapeutics CEO And CFO Talk Company Finances, Partnerships And Pipeline",2016-12-07 12:28:00-05:00,KPTI,neutral
741566.0,Karyopharm Therapeutics' Top Execs Talk Recent Results In Multiple Myeloma And Acute Myeloid Leukemia,2016-12-06 15:41:00-05:00,KPTI,positive
741567.0,Karyopharm Presents STOMP Phase 1b Data At ASH; STOMP Continues To Demonstrate High Response Rates In Combination With Bortezomib And Pomalidomide,2016-12-05 17:47:00-05:00,KPTI,neutral
741568.0,"American Society Of Hematology (ASH) Meeting Presenters Tonight Include Karyopharm, bluebird bio, Alnylam, Juno Therapeutics, Stemline Therapeutics, Kite Pharma, Beigene, & Prothena",2016-12-05 15:09:00-05:00,KPTI,neutral
741569.0,Karyopharm Presents Updated Phase 2b STORM Data at ASH 2016,2016-12-05 03:57:00-05:00,KPTI,neutral
741570.0,Karyopharm Presents Updated Phase 2 SAIL Relapsed/Refractory AML Clinical Data at ASH 2016,2016-12-04 17:09:00-05:00,KPTI,positive
741571.0,"American Society Of Hematology Meeting Begins Dec. 3rd, Day 1 of 4",2016-12-02 10:53:00-05:00,KPTI,neutral
741572.0,Jefferies London Health Care Conference Continues Today,2016-11-17 10:14:00-05:00,KPTI,positive
741573.0,"Karyopharm Reports Q3 Loss/Share $0.69 vs Est Loss/Share $0.81, Rev $48K vs $40K Est",2016-11-07 16:57:00-05:00,KPTI,neutral
741574.0,Wellington Management Reports 11.83% Stake in Karyopharm Therapeutics in 13G,2016-10-11 10:39:00-04:00,KPTI,neutral
741575.0,European Society For Medical Oncology Conference Commences Today (Oct.7 Thru Oct. 11),2016-10-07 08:09:00-04:00,KPTI,neutral
741576.0,"Karyopharm Says 'Single-Agent Selinexor Demonstrates Robust Clinical Benefit and Favorable Tolerability in Patients with Heavily Pre-treated Gynecologic Cancers,' Will Present Updated SIGN Phase 2 Data at ESMO",2016-10-05 06:20:00-04:00,KPTI,positive
741577.0,"Abstracts Expected Wednesday From Companies Presenting At The European Society For Medical Oncology Conf. Beginning Oct. 7th, Including From Karyopharm Therapeutics, Kite Pharma And Clovis Oncology",2016-10-04 08:35:00-04:00,KPTI,neutral
741578.0,Karyopharm Reports Publishing of Preclinical Data Show Selinexor's Potential in KRAS-Mutant NSCLC,2016-09-29 07:35:00-04:00,KPTI,neutral
741579.0,Karyopharm Publishes Preclinical and Phase 1 Clinical Data for Selinexor in Ovarian Cancer in Clinical Cancer Research Publication,2016-09-28 07:30:00-04:00,KPTI,negative
741580.0,10 Biggest Mid-Day Losers For Tuesday,2016-09-06 13:03:00-04:00,KPTI,negative
741581.0,Mid-Day Market Update: Navistar Rises After Strategic Alliance With Volkswagen Truck & Bus; Tonix Shares Drop,2016-09-06 12:08:00-04:00,KPTI,neutral
741582.0,"Wedbush Defending Karyopharma, Says Selinexor Displays Meaningful Activity In STORM, Maintains Outperform and $14 PT",2016-09-06 12:08:00-04:00,KPTI,positive
741583.0,"10 Stocks Which Rallied Four Days, Then Sold Off On Friday",2016-09-06 11:38:00-04:00,KPTI,neutral
741584.0,15 Stocks Moving In Tuesday's Pre-Market Session,2016-09-06 08:22:00-04:00,KPTI,neutral
741585.0,Karyopharm Reports 2b STORM Results Show Response Rates Of 20.8% In Quad-Refractory & 20% InPenta-Refractory Disease; Will Expand Study To Include 120 Patients With Penta-Refractory Myeloma To Support Accelerated Approval,2016-09-06 07:09:00-04:00,KPTI,positive
741586.0,"Adam Feuerstein @adamfeuerstein Tweet: $KPTI Penta-refractory multiple myeloma. That such a classification exists illustrates progress made in MM, but also competitive challenge.",2016-09-06 07:07:00-04:00,KPTI,positive
741587.0,Mid-Afternoon Market Update: Crude Oil Down 1.3%; Ritchie Bros. Shares Spike Higher,2016-08-30 14:34:00-04:00,KPTI,negative
741588.0,18 Biggest Mid-Day Gainers For Tuesday,2016-08-30 12:51:00-04:00,KPTI,neutral
741589.0,UPDATE: Karyopharm Therapeutics Sasy to Add ~120 Patients With Penta-Refractory MM,2016-08-30 12:19:00-04:00,KPTI,neutral
741590.0,Karyopharm Therapeutics Says Intends To Expand Its Phase 2B Storm Study Evaluating Activity Of Selinexor In Multiple Myeloma,2016-08-30 12:17:00-04:00,KPTI,positive
741591.0,Mid-Day Market Update: Abercrombie & Fitch Drops On Wider Loss; Rigel Pharmaceuticals Shares Surge,2016-08-30 12:15:00-04:00,KPTI,neutral
741592.0,Mid-Morning Market Update: Markets Mostly Flat; G-III Apparel Misses Q2 Expectations,2016-08-30 10:12:00-04:00,KPTI,negative
741593.0,Jefferies Upgrades Karyopharm To Buy As STORM Data Likely To Predict Sunny Skies,2016-08-30 09:58:00-04:00,KPTI,positive
741594.0,5 Biggest Price Target Changes For Tuesday,2016-08-30 09:36:00-04:00,KPTI,neutral
741595.0,Benzinga's Top Upgrades,2016-08-30 08:47:00-04:00,KPTI,positive
741596.0,"Jefferies Upgrades Karyopharm Therapeutics to Buy, Raises PT to $12.00",2016-08-30 07:00:00-04:00,KPTI,neutral
741597.0,Benzinga's Top Initiations,2016-08-18 09:32:00-04:00,KPTI,positive
741598.0,"H.C. Wainwright Initiates Coverage on Karyopharm Therapeutics at Buy, Announces $15.00 PT",2016-08-18 07:11:00-04:00,KPTI,neutral
741599.0,Karyopharm Reports Q2 EPS $(0.84) vs $(0.76) Est.,2016-08-04 07:56:00-04:00,KPTI,neutral
741600.0,UPDATE: Karyopharm Reports Orphan Drug Designation for Selinexor,2016-07-27 07:38:00-04:00,KPTI,neutral
741601.0,Karyopharm Reports Phase 1b Selinexor Sarcoma Data: is 'Early Evidence of Anticancer Activity in Advanced Sarcoma and Inform Recommended Phase 2 Dose',2016-07-27 07:37:00-04:00,KPTI,positive
741602.0,Benzinga's Top Initiations,2016-06-28 09:16:00-04:00,KPTI,positive
741603.0,Baird Initiates Coverage on Karyopharm Therapeutics at Outperform,2016-06-28 06:39:00-04:00,KPTI,neutral
741604.0,Karyopharm Commences First Stage Clinical Study With KPT-9274,2016-06-22 10:26:00-04:00,KPTI,neutral
741605.0,Karyopharm Begins Phase 1 Clinical Trial with KPT-9274,2016-06-22 07:30:00-04:00,KPTI,neutral
741606.0,"Karyopharm Offers Outline for Key Selinexor Development Achievements: Enrollment Closed, Patient Dosing Underway in Phase 1b Trial",2016-06-16 07:30:00-04:00,KPTI,neutral
741607.0,"Karyopharm Presents Preliminary STOMP Phase 1b Clinical Data, Updated Clinical Data Shows High Response Rates When Selinexor Is Combined with Standard of Care Agents in Heavily Pretreated Patients with Multiple Myeloma",2016-06-10 07:32:00-04:00,KPTI,positive
741608.0,Benzinga's Top Initiations,2016-05-27 09:29:00-04:00,KPTI,positive
741609.0,Raymond James Initiates Coverage on Karyopharm Therapeutics at Outperform,2016-05-27 09:21:00-04:00,KPTI,neutral
741610.0,Raymond James Initiates Coverage on Karyopharm Therapeutics at Outperform,2016-05-27 09:02:00-04:00,KPTI,neutral
741611.0,Karyopharm Q1 EPS ($0.75) vs ($0.74) est,2016-05-09 07:34:00-04:00,KPTI,neutral
741612.0,Karyopharm Offers Data Showing Potential of Nuclear XPO1 Inhibition in Treatment of Traumatic Brain Injury,2016-04-20 07:09:00-04:00,KPTI,negative
741613.0,Karyopharm Receives NIAID Grant to Advance Development of KPT-350 for the Treatment of Lupus,2016-03-31 08:30:00-04:00,KPTI,positive
741614.0,"Bank of America Downgrades Karyopharm Therapeutics to Underperform, Lowers PT to $11.00",2016-03-15 08:31:00-04:00,KPTI,negative
741615.0,"JP Morgan Maintains Overweight on Karyopharm Therapeutics, Lowers PT to $19.00, Believes Selinexor's Unique Mechanism Of Action Will Prove Useful In Several Oncology Indications",2016-03-14 11:47:00-04:00,KPTI,positive
741616.0,Karyopharm Therapeutics Reports Q4 EPS $(0.81) vs $(0.82) Est.,2016-03-14 07:31:00-04:00,KPTI,neutral
741617.0,"Karyopharm's Selinexor First-in-Human Phase 1 Clinical Trial Data Published in Journal of Clinical Oncology, Expects Phase 2/3 SCORE Study Initiation In Mid-2016",2016-03-04 07:08:00-05:00,KPTI,neutral
741618.0,FDA Approves First Drug To Produce Evidence Of Survival Benefits in Lipsarcoma,2016-01-28 13:07:00-05:00,KPTI,positive
741619.0,Karyopharm Reports Initiation of Clinical Trial of Oral Selinexor in Advanced Liposarcoma; Phase 2/3 SEAL Trial Initiated,2016-01-14 07:03:00-05:00,KPTI,positive
741620.0,"Jefferies Downgrades Karyopharm Therapeutics to Hold, Lowers to $14.00",2016-01-06 06:24:00-05:00,KPTI,negative
741621.0,Mid-Afternoon Market Update: Dow Jumps Over 150 Points; Steelcase Shares Dip Following Weak Results,2015-12-22 14:59:00-05:00,KPTI,negative
741622.0,Mid-Day Market Update: Cintas Gains On Earnings Beat; NetApp Shares Slide,2015-12-22 12:20:00-05:00,KPTI,positive
741623.0,Mid-Morning Market Update: Markets Edge Higher; ConAgra Posts Mixed Q2 Results,2015-12-22 10:06:00-05:00,KPTI,neutral
741624.0,Karyopharm Therapeutics Shows Positive Clinical Data on the Activity of Selinexor in Combination with Other Anticancer Agents across Multiple Hematologic Malignancies at the 2015 American Society of Hematology Meeting,2015-12-07 10:01:00-05:00,KPTI,positive
741625.0,Leerink Highlights Biotechs Poised To Benefit From ASH Conference,2015-11-30 13:13:00-05:00,KPTI,positive
741626.0,"Amira Nature Foods, AlarmCom, Flotek Moving In Tuesday's After Hours Session",2015-11-10 17:05:00-05:00,KPTI,neutral
741627.0,Karyopharm Reports Q3 EPS $(0.85) vs $(0.87) Est.,2015-11-09 07:35:00-05:00,KPTI,neutral
741628.0,Karyopharm Initiates STOMP Clinical Trial of Oral Selinexor in Multiple Myeloma,2015-10-19 08:03:00-04:00,KPTI,neutral
741629.0,Biotech Investors Still Have Opportunity,2015-09-09 11:20:00-04:00,KPTI,positive
741630.0,4 More Biotechs Leerink Is Looking At Post-Earnings,2015-08-11 14:26:00-04:00,KPTI,neutral
741631.0,Mid-Day Market Update: Dow Surges Over 200 Points; Dean Foods Shares Decline On Downbeat Sales,2015-08-10 13:34:00-04:00,KPTI,positive
741632.0,"Mid-Day Market Update: Monday's Movers, China's Trade, Oil And More",2015-08-10 12:29:00-04:00,KPTI,neutral
741633.0,Mid-Morning Market Update: Markets Open Higher; Berkshire Hathaway To Acquire Precision Castparts For $37.2B,2015-08-10 10:50:00-04:00,KPTI,neutral
741634.0,Morning Market Losers,2015-08-10 09:59:00-04:00,KPTI,negative
741635.0,Karyopharm Reports Q2 EPS $(0.92) vs. Est. $(0.77),2015-08-10 07:30:00-04:00,KPTI,neutral
741636.0,Benzinga's Top Initiations,2015-07-17 09:11:00-04:00,KPTI,positive
741637.0,"Bank of America Initiates Coverage on Karyopharm Therapeutics at Neutral, Announces $32.00 PT",2015-07-17 09:04:00-04:00,KPTI,neutral
741638.0,US Stock Futures Signal Higher Start On Wall Street,2015-06-22 07:58:00-04:00,KPTI,neutral
741639.0,Karyopharm Presents Hematologic Cancer Data on Lead Drug Candidate Selinexor at International Conference on Malignant Lymphoma,2015-06-22 07:02:00-04:00,KPTI,negative
741640.0,JMP Sees A 'Negative Market Tone' In Biotechnology,2015-06-15 13:31:00-04:00,KPTI,negative
741641.0,"Leerink: Karyopharm Therapeutics Still A Buy, Cash Can Last Until 2018",2015-06-15 11:04:00-04:00,KPTI,neutral
741642.0,Karyopharm Presents Hematologic Cancer Data on Lead Drug Candidate Selinexor at European Hematology Association Annual Meeting,2015-06-15 07:04:00-04:00,KPTI,negative
741643.0,Karyopharma Says Selinexor Shows 38% Disease Control & 13% Overall Response Rate,2015-06-01 14:17:00-04:00,KPTI,neutral
741644.0,Karyopharm Presents Positive Clinical Data for KPT-330 at ASCO,2015-05-30 20:36:00-04:00,KPTI,positive
741645.0,Karyopharm Begins STORM Clinical Trial of Oral Selinexor (KPT-330) in Multiple Myeloma,2015-05-28 08:01:00-04:00,KPTI,neutral
741646.0,Karyopharm to Showcase Clinical Data Update for Selinexor (KPT-330) in Solid Tumors,2015-05-27 16:17:00-04:00,KPTI,positive
741647.0,US Stock Futures Edge Lower Ahead Of Economic Data,2015-05-21 07:58:00-04:00,KPTI,negative
741648.0,Karyopharm Announces Will Present Data on Selinexor at EHA Annual Meeting on Jun 11-14,2015-05-21 07:28:00-04:00,KPTI,neutral
741649.0,Karyopharm to Showcase Hematologic Cancer Data on Lead Drug Candidate Selinexor at European Hematology Association Annual Meeting,2015-05-21 07:26:00-04:00,KPTI,negative
741650.0,Leerink Is Changing Targets At These 7 Biotechs,2015-05-12 12:54:00-04:00,KPTI,neutral
741651.0,Karyopharm Reports Q1 Loss of $0.74/Share vs Loss of $0.75/Share Est.,2015-05-11 07:13:00-04:00,KPTI,negative
741652.0,Biotech Investors: May 29th Could Be A Big Day,2015-04-21 14:39:00-04:00,KPTI,neutral
741653.0,Karyopharm Reports Granted US Composition-of-Matter Patent for Selinexor,2015-04-13 08:33:00-04:00,KPTI,positive
741654.0,5 Biotech Stocks On JMP's Radar,2015-03-20 15:15:00-04:00,KPTI,neutral
741655.0,"Karyopharm Therapeutics Q4 EPS -$0.79 Vs Est -$0.69, Sales $16K Vs $40K",2015-03-16 07:02:00-04:00,KPTI,neutral
741656.0,"Earnings Scheduled For March 16, 2015",2015-03-16 04:34:00-04:00,KPTI,neutral
741657.0,18 Biotech Stocks These Wall Street Analysts Are Tracking,2015-03-11 12:04:00-04:00,KPTI,neutral
741658.0,Why JMP Securities Is Watching (And Loving) These 3 Biotech Stocks,2015-02-24 16:42:00-05:00,KPTI,positive
741659.0,Karyopharm Therapeutics Announces Nature Neuroscience Publishes Data Demonstrating Potential Therapeutic Benefits of Karyopharm's SINE(TM) In Multiple Sclerosis,2015-02-23 11:02:00-05:00,KPTI,positive
741660.0,Biotechs Presenting At The J.P. Morgan Healthcare Conference: Day 2,2015-01-12 11:03:00-05:00,KPTI,neutral
741661.0,Karyopharm Reports Orphan Drug Designation Granted for Selinexor in Multiple Myeloma,2015-01-08 08:31:00-05:00,KPTI,positive
741662.0,Mid-Afternoon Market Update: Dow Jumps Over 200 Points After Fed Minutes; RPM Shares Drop On Downbeat Results,2015-01-07 15:17:00-05:00,KPTI,neutral
741663.0,Mid-Day Market Update: J C Penney Jumps On Strong Holiday Sales; Micron Shares Decline,2015-01-07 13:11:00-05:00,KPTI,positive
741664.0,4 More Biotech Secondaries Investors Are Watching,2015-01-07 12:50:00-05:00,KPTI,neutral
741665.0,Mid-Morning Market Update: Markets Surge; Monsanto Profit Tops Estimates,2015-01-07 10:59:00-05:00,KPTI,positive
741666.0,Morning Market Losers,2015-01-07 09:50:00-05:00,KPTI,negative
741667.0,Wednesday Morning Movers,2015-01-07 09:17:00-05:00,KPTI,neutral
741668.0,Karyopharm Therapeutics Prices 3M Share Offering @$33.00/Share,2015-01-07 05:01:00-05:00,KPTI,positive
741669.0,4 Biotech Secondary Offerings Traders Are Watching,2015-01-06 13:05:00-05:00,KPTI,neutral
741670.0,From S-3: Karyopharm Therapeutics Files Automatic Mixed Shelf Offering,2015-01-05 16:44:00-05:00,KPTI,neutral
741671.0,Karyopharm Announces Addition to the NASDAQ Biotechnology Index,2014-12-15 08:59:00-05:00,KPTI,neutral
741672.0,Mid-Afternoon Market Update: Oxford Industries Drops On Downbeat Results; Office Depot Shares Spike Higher,2014-12-11 15:59:00-05:00,KPTI,positive
741673.0,"Mid-Day Losers From December 11: RadioShack, Lee Enterprises, Karyopharm Therapeutics, Oxford Industries, Comtech",2014-12-11 13:51:00-05:00,KPTI,negative
741674.0,Karyopharm Initiates Third Registration-Directed Clinical Trial of Oral Selinexor,2014-12-11 08:02:00-05:00,KPTI,neutral
741675.0,Karyopharm Presents Positive Clinical Data For Selinexor In NHL Patients,2014-12-08 13:35:00-05:00,KPTI,positive
741676.0,Karyopharm Reports Positive Combo Data for Selinexor in MM Patients,2014-12-08 13:01:00-05:00,KPTI,positive
741677.0,Karyopharma Reports Added Orphan Designations Granted for KPT-330 by EC,2014-12-01 08:06:00-05:00,KPTI,positive
741678.0,Karyopharma Offers Data on Oncology Pipeline at EORTC-NCI-AACR Annual Meeting,2014-11-24 08:05:00-05:00,KPTI,neutral
741679.0,Karyopharm Initiates Registration-Directed Clinical Study Of Selinexor (KPT-330) In Patients With Richter's Transformation,2014-11-10 07:07:00-05:00,KPTI,neutral
741680.0,Karyopharm Initiates Phase 2 Study of Selinexor in Patients With Richter's Transformation,2014-11-10 07:02:00-05:00,KPTI,neutral
741681.0,"Oppenheimer Upgrades Karyopharm Therapeutics to Outperform, Announces $53.00 PT",2014-11-10 05:50:00-05:00,KPTI,neutral
741682.0,"Barrington Research Initiates Coverage on Karyopharm Therapeutics at Buy, Announces $54.00 PT",2014-11-04 17:27:00-05:00,KPTI,neutral
741683.0,Karyopharm Expands Global Presence With European Subsidiary,2014-10-27 08:17:00-04:00,KPTI,positive
741684.0,UPDATE: Webush Initiates Coverage On Karyopharm Therapeutics Inc On Selinexor Potential,2014-10-07 11:13:00-04:00,KPTI,neutral
741685.0,"Wedbush Initiates Coverage on Karyopharm Therapeutics at Outperform, Announces $50.00 PT",2014-10-06 17:55:00-04:00,KPTI,neutral
741686.0,Stocks Continue Lower On Merger Monday,2014-09-29 17:24:00-04:00,KPTI,negative
741687.0,Endologix Drops On Weak Forecast; TIBCO Software Shares Spike Higher,2014-09-29 14:59:00-04:00,KPTI,negative
741688.0,"Midday Losers From September 29 - Tonix Pharmaceuticals Holding Corp., Digital Ally, Inc. And More",2014-09-29 13:58:00-04:00,KPTI,negative
741689.0,Markets Open Lower; Encana To Acquire Athlon Energy For $5.93 Billion,2014-09-29 11:14:00-04:00,KPTI,neutral
741690.0,Morning Market Losers ,2014-09-29 09:48:00-04:00,KPTI,negative
741691.0,Karyopharm Reports Clinical Data for Selinexor in Advanced Solid Tumors,2014-09-29 08:01:00-04:00,KPTI,positive
741692.0,Karyopharm Announces Clinical Data For Selinexor (KPT-330) In Advanced Solid Tumors,2014-09-29 08:01:00-04:00,KPTI,positive
741693.0,Karyopharm Announces Justin Renz CFO,2014-08-08 07:32:00-04:00,KPTI,neutral
741694.0,Karyopharm Therapeutics Reports Q2 EPS of $(0.55) vs $(0.50) Est; Revenue of $21.0M vs $150.0K Est,2014-08-07 07:19:00-04:00,KPTI,neutral
741695.0,Oppenheimer Initiates Coverage on Karyopharm Therapeutics at Market Perform,2014-07-08 06:24:00-04:00,KPTI,neutral
741696.0,Karyopharm Therapeutics Shares Spike Lower,2014-07-01 14:13:00-04:00,KPTI,neutral
741697.0,US Stock Futures Drop Ahead Of Consumer Sentiment Report,2014-06-27 07:41:00-04:00,KPTI,negative
741698.0,Karyopharm Therapeutics Prices 2.647M Share Offering at $42.50/Share,2014-06-27 05:32:00-04:00,KPTI,positive
741699.0,"Karyopharm Therapeutics Announces Offering of 2.2M Shares, 2M by Co., 200K Shares by Selling Holders",2014-06-25 16:03:00-04:00,KPTI,positive
741700.0,Karyopharm Therapeutics to Offer Up to $115M in Stock,2014-06-19 06:21:00-04:00,KPTI,neutral
741701.0,Mid-Afternoon Market Update: US Stocks Reverse Earlier Loses; Fusion-io Shares Jump On SanDisk Buyout,2014-06-16 15:03:00-04:00,KPTI,neutral
741702.0,"Mid-Day Market Movers For Monday, June 16, 2014",2014-06-16 12:52:00-04:00,KPTI,neutral
741703.0,Mid-Day Market Update: US Stocks Turn Red; Fusion-IO Shares Jump On SanDisk Buyout,2014-06-16 12:23:00-04:00,KPTI,positive
741704.0,​Mid-Morning Market Update: Markets Mostly Higher; Medtronic To Acquire Covidien For $42.9B,2014-06-16 10:24:00-04:00,KPTI,neutral
741705.0,Morning Market Losers ,2014-06-16 09:48:00-04:00,KPTI,negative
741706.0,"UPDATE: Karyopharma Announces FDA Sees Effectiveness, Safety for KPT-335",2014-06-16 08:46:00-04:00,KPTI,positive
741707.0,"Karyopharma Announces FDA Sees Effectiveness, Safety for KPT-335",2014-06-16 08:46:00-04:00,KPTI,positive
741708.0,"Veristat, Karyopharm Therapeutics Enter into Preferred Provider Agreement for Oncology and Novel Therapeutic Advancement ",2014-06-15 16:39:00-04:00,KPTI,positive
741709.0,Karyopharm Reports First Combination Data of Selinexor With Low-Dose Dexamethasone in Heavily Pretreated Multiple Myeloma Patients,2014-06-13 05:59:00-04:00,KPTI,neutral
741710.0,13G Filing from Franklin Resources on Karyopharma Therapeutics Shows Increased Stake from 6.78% as of Mar. 31st to 11.9%,2014-06-10 12:53:00-04:00,KPTI,positive
741711.0,"Karyopharm Offers Updates for Selinexor in Solid Tumors at ASCO 2014, Data Showed Continued Anti-Cancer Evidence",2014-06-02 07:43:00-04:00,KPTI,positive
741712.0,Karyopharm Reports Selinexor Shows Continued Evidence of Anti-Cancer Activity in NHL and AML at ASCO ,2014-05-31 15:09:00-04:00,KPTI,positive
741713.0,Karyopharm Announces Second Orphan Drug Designation for Selinexor in Diffuse Large B-Cell Lymphoma (DLBCL),2014-05-20 08:08:00-04:00,KPTI,neutral
741714.0,Karyophorm Announces Drug for Acute Myeloid Leukemia Receives Orphan Drug Designation,2014-05-19 08:16:00-04:00,KPTI,neutral
741715.0,FDA Announces Karyopharm's Selinexor Wins Orphan Drug Designation,2014-05-16 16:06:00-04:00,KPTI,positive
741716.0,Karyopharm Therapeutics Reports Q1 EPS of $(0.46) vs $(0.47) Est; Revenue of $171.0M vs $160.0K Est,2014-05-07 16:54:00-04:00,KPTI,neutral
741717.0,Karyopharm Therapeutics Initiates Phase 2 Study of Selinexor,2014-04-29 16:15:00-04:00,KPTI,neutral
741718.0,Karyopharm Initiates Phase 2 Study of Selinexor in Patients With Advanced Gynecologic Malignancies,2014-04-24 07:02:00-04:00,KPTI,positive
741719.0,Karyopharm Announces Five Clinical Data Presentations at ASCO,2014-04-22 07:10:00-04:00,KPTI,neutral
741720.0,US Stock Futures Up Ahead Of Earnings,2014-04-21 07:31:00-04:00,KPTI,neutral
741721.0,"Karyopharm Announces a Phase 1 Trial of Selinexor (KPT-330) in Pediatric Patients With Relapsed Acute Lymphoblastic Leukemia, Acute Myeloid Leukemia",2014-04-21 07:06:00-04:00,KPTI,neutral
741722.0,Karyopharm Announces Initiation of a Phase 1 Study of Decitabine (Dacogen) and Selinexor (KPT-330) in Acute Myeloid Leukemia (AML) ,2014-04-15 16:06:00-04:00,KPTI,neutral
741723.0,Karyopharm Appoints Chris Primiano as General Counsel,2014-04-10 16:15:00-04:00,KPTI,neutral
741724.0,Karyopharm Names Chris Primiano as General Counsel,2014-04-10 16:14:00-04:00,KPTI,neutral
741725.0,"Karyopharm Announces Entered Into Preferred Provider Deal with Clinipace Worldwide, No Terms Disclosed",2014-04-09 10:04:00-04:00,KPTI,negative
741726.0,Karyopharm Therapeutics Files for $115M Offering of Common Stock,2014-03-24 06:29:00-04:00,KPTI,neutral
741727.0,UPDATE: Bank of America Reiterates on Karyopharm Therapeutics on Significant Catalysts in 2014,2014-03-06 09:33:00-05:00,KPTI,positive
741728.0,"Bank of America Maintains Buy on Karyopharm Therapeutics, Raises PO to $48.00",2014-03-06 07:02:00-05:00,KPTI,negative
741729.0,Adam Feuerstein Tweets: 'JMP's Mike King raised his WW sales estimate on $KPTI lead drug selinexor to $6.7B from $3.4B based on PLANS for more ph2 studies.',2014-03-05 17:16:00-05:00,KPTI,neutral
741730.0,Karyopharm Therapeutics Reports 2013 Loss/Share $5.59,2014-03-05 06:36:00-05:00,KPTI,neutral
741731.0,"Karyopharm Reports Data on Selinexor, Says Shows Anti-Tumor Activity",2014-01-22 08:31:00-05:00,KPTI,neutral
741732.0,Karyopharm Reports Award of Grant from National MS Society to Further Develop SINE Compounds,2014-01-08 08:37:00-05:00,KPTI,positive
741733.0,Karyopharm Therapeutics Presents Promising Selinexor Data at ASH,2013-12-08 21:04:00-05:00,KPTI,positive
741734.0,UPDATE: Bank of America Initiates Coverage on Karyopharm Therapeutics on Novel Cancer Platform with Broad Potential,2013-12-02 09:02:00-05:00,KPTI,negative
741735.0,UPDATE: Oppenheimer Initiates Coverage on Karyopharm Therapeutics on Novel Mechanism with Broad Applicability in Oncology,2013-12-02 08:31:00-05:00,KPTI,positive
741736.0,"JMP Securities Initiates Coverage on Karyopharm Therapeutics at Outperform, Announces $25.00 PT",2013-12-02 08:18:00-05:00,KPTI,positive
741737.0,"Bank of America Initiates Coverage on Karyopharm Therapeutics at Buy, Announces $24.00 PO",2013-12-02 06:26:00-05:00,KPTI,negative
741738.0,"Oppenheimer Initiates Coverage on Karyopharm Therapeutics at Outperform, Announces $23.00 PT",2013-12-02 06:20:00-05:00,KPTI,neutral
741739.0,IPO for Karyopharm Therapeutics Opens at $17.86/Share After Pricing at $16,2013-11-06 10:36:00-05:00,KPTI,neutral
741740.0,"Quotes for IPO of Karyopharm Therapeutics Now Available, Issue Expected to Open for Trade at 10:25AM EST",2013-11-06 10:13:00-05:00,KPTI,neutral
